CurrentNeighborhood Health Plan of Rhode IslandPolicy 118-A 08-2021

Oral Isotretinoin Prior Authorization

Defines prior authorization criteria for all oral isotretinoin products (brand and generic) for members of Neighborhood Health Plan of Rhode Island; applies to initial authorization and limited retreatment courses.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyOral Isotretinoin Prior Authorization

Policy CodePolicy 118-A 08-2021

Change TypeNo material change

Effective DateAug 1, 2021

Next Review Date

Key ActionObtain prior authorization showing diagnosis and documentation of inadequate response to a topical acne product and an oral antibiotic.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

15-20 wkssingle course

>=8 wksretreatment interval

40 wksmax duration

5 mmnodule size

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Primary diagnosis requirement: The patient has any of the following diagnoses: A) severe recalcitrant nodular acne vulgaris, B) refractory acne vulgaris, C) severe refractory rosacea

Prior therapy requirement for acne/rosacea: The patient has tried and had an inadequate treatment response to any topical acne product AND an oral antibiotic

Alternate covered diagnoses (compendial uses): The patient has any of the following diagnoses: A) neuroblastoma, B) cutaneous T-cell lymphoma (CTCL) including mycosis fungoides and Sezary syndrome, C) is at high risk for developing skin cancer (squamous cell cancers), D) ichthyosis, E) pityriasis rubra pilaris

These are listed as compendial uses and allowable indications

Retreatment limit: Treatment limited to 40 weeks (2 courses) or less AND with at least 8 weeks between each course<= 40 weeks total; >= 8 weeks between courses

Use of oral isotretinoin in females who are pregnant is contraindicated because isotretinoin can cause severe birth defects. The policy reserves isotretinoin for non-pregnant patients; female patients must not be pregnant when therapy is initiated or continued. (See FDA-approved indications and product labeling for specific pregnancy-related requirements.)

Coding and Treatment Timing

Covered oral isotretinoin products (brand/generic)mixed

Absorica (isotretinoin)	Brand oral isotretinoin product listed
Absorica LD (isotretinoin)	Brand oral isotretinoin product listed
Accutane (isotretinoin)	Brand oral isotretinoin product listed
Amnesteem (isotretinoin)	Brand oral isotretinoin product listed
Claravis (isotretinoin)	Brand oral isotretinoin product listed
Myorisan (isotretinoin)	Brand oral isotretinoin product listed
Zenatane (isotretinoin)	Brand oral isotretinoin product listed

inv-04: Retreatment interval — minimum interval before retreatment

Minimum interval before retreatment>= 8 weeks after completion of the first course

RationalePatients may continue to improve off isotretinoin; a second course should not be initiated until at least 8 weeks after completion

Related limitRetreatment contributes to a maximum cumulative treatment limit of 40 weeks (two courses)

inv-05: Single course duration — typical single course length

Typical single course duration15–20 weeks

Clinical effectA single 15–20 week course often produces complete and prolonged remission in many patients

Implication for retreatment timingBecause improvement can continue after completion, wait >= 8 weeks before considering a second course

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for all oral isotretinoin products listed; approval granted when diagnostic and prior-therapy criteria are met.

Affected products: all oral isotretinoin brands (Absorica, Absorica LD, Accutane, Amnesteem, Claravis, Myorisan, Zenatane)
Type: Initial Prior Authorization
Status: CVS Caremark Criteria

Step Therapy

Step Therapy Requirement

Patient must have tried topical therapy AND an oral antibiotic before isotretinoin is approved.

Step requirement applies to initial therapy requests

Documentation Required

Required Documentation and Denial Risk

Documentation must show the diagnosis and prior treatment failure with at least one topical acne product and an oral antibiotic. Requests may be denied if documentation does not demonstrate one of the listed diagnoses or prior inadequate response to both a topical acne product and an oral antibiotic.

Required diagnoses: severe recalcitrant nodular acne vulgaris; refractory acne vulgaris; severe refractory rosacea
Required prior therapy: at least one topical acne product AND an oral antibiotic with inadequate response

Background

Isotretinoin is indicated for severe recalcitrant nodular acne—defined as multiple inflammatory nodules ≥ 5 mm in diameter and disease that is unresponsive to conventional therapies, including systemic antibiotics. Because of its significant adverse effects, isotretinoin is reserved for patients who have failed standard topical and oral treatments. A typical single course is 15–20 weeks, which often yields complete and prolonged remission; if retreatment is needed, it should be delayed at least 8 weeks after completion of the prior course to allow continued off‑therapy improvement.

Definitions

inv-12: Severe recalcitrant nodular acne — definition including nodule size threshold

DefinitionAcne with multiple inflammatory nodules 5 mm or greater in diameter

Severity criterion'Severe' implies many (as opposed to few or several) nodules and unresponsiveness to conventional therapy, including systemic antibiotics

Clinical featuresNodules may become suppurative or hemorrhagic

Population noteIndication applies to non-pregnant patients (12 years of age and older for Absorica/Absorica LD) due to teratogenic risk

Revision History

2021-08-01policy_effective

Policy effective date; defines prior authorization criteria for all oral isotretinoin products with coverage criteria, prior-therapy requirements, and retreatment limits.

2021-08-20policy_review

Last review date recorded for the isotretinoin prior authorization policy.

2021-08-?document_versioning

Policy version labeled 118-A 08-2021 referencing CVS Caremark criteria and package insert sources (2020–2021) supporting indications and retreatment guidance.

2021-08-01clinical_guidanceLatest

Guidance specifies single course duration of 15–20 weeks and that a second course should not be initiated until at least 8 weeks after completion of the first course.